Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to

Drug
active
Indication
Arthritis, Psoriatic

Other upcoming events for MLTX

Phase 3 ReadoutPhase 3 Topline: An Open-label, Single-arm Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Soneloki
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Parallel-group, Randomized, Double-blind, 4-arm, Placebo-controlled, Multicenter Study Wi
Phase 3 ReadoutPhase 3 Topline: A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in
Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, a

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Parallel-group, Randomized, Double-blind, 3-arm, Placebo-controlled, Multicenter Study to — MLTX Phase 3 Readout | BioSniper